MEDINET Co., Ltd.
Notice Regarding Implementation of Business Restructuring
MEDINET Co., Ltd. will implement a business restructuring to refocus resources on cell processing operations by reviewing contract manufacturing (CDMO) of specified cell-processed products supporting cancer immunocyte therapies and regenerative medicine product development. Fixed cost reductions of 300 million yen are expected in the fiscal year ending September 2027, and approximately 600 million yen per year thereafter from the fiscal year ending September 2028. A voluntary retirement program targeting about 20 people will be conducted.
Key Figures
- Fixed cost reduction: 300 million yen (expected in fiscal year ending September 2027)
- Fixed cost reduction: approx. 600 million yen/year (from fiscal year ending September 2028)
- Voluntary retirement recruitment: approx. 20 people (excluding manufacturing division)
AI要約
Key Points of the Business Restructuring
The Company will review resource allocation between contract manufacturing for regenerative medicine products (CDMO) and development of regenerative medicine products. By strengthening quality verification of specified cell-processed products and concentrating management resources on cell processing operations, the Company aims to improve profitability and strengthen its financial foundation to establish stable business operations. The review of regenerative medicine product businesses and prioritization of R&D will proceed to simultaneously enhance the profitability of existing businesses and improve management efficiency.
Future Impact and Personnel Adjustments
As part of organizational optimization, a voluntary retirement program will be implemented, targeting approximately 20 people. The retirement date is February 28, 2027, and the application period is scheduled from December 10, 2026 to December 24, 2026, with special lump-sum payments and reemployment support provided. Restructuring one-time costs are expected to be 50 million yen in the fiscal year ending September 2027, and impacts from fiscal year 2028 onward will be reflected in disclosed earnings guidance.
MEDINET Co., Ltd.
Company overview · Stock price · Financial data · All IR
